SciVision Biotech Future Growth
Future criteria checks 2/6
SciVision Biotech is forecast to grow revenue at 41.4% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Medical Equipment earnings growth | 22.1% |
Revenue growth rate | 41.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 18 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Is Now The Time To Put SciVision Biotech (TWSE:1786) On Your Watchlist?
Oct 11SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Aug 30SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's
Jul 22SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50
Jun 28SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Jun 14SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly
Jun 04Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio
Apr 01Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Apr 20SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital
Apr 02Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?
Mar 15Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Feb 25Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?
Feb 05Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Jan 18Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?
Jan 01SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years
Dec 14Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Nov 25Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 1,431 | N/A | N/A | 555 | 1 |
12/31/2024 | 1,036 | N/A | N/A | 494 | 1 |
9/30/2024 | 831 | 216 | 223 | 251 | N/A |
6/30/2024 | 815 | 213 | 283 | 299 | N/A |
3/31/2024 | 788 | 197 | 291 | 305 | N/A |
12/31/2023 | 713 | 178 | 257 | 272 | N/A |
9/30/2023 | 670 | 168 | 205 | 227 | N/A |
6/30/2023 | 628 | 159 | 192 | 212 | N/A |
3/31/2023 | 577 | 148 | 151 | 169 | N/A |
12/31/2022 | 557 | 142 | 167 | 182 | N/A |
9/30/2022 | 538 | 138 | 151 | 162 | N/A |
6/30/2022 | 500 | 112 | 84 | 97 | N/A |
3/31/2022 | 495 | 104 | 116 | 129 | N/A |
12/31/2021 | 506 | 102 | 73 | 99 | N/A |
9/30/2021 | 497 | 112 | 98 | 159 | N/A |
6/30/2021 | 491 | 126 | 65 | 129 | N/A |
3/31/2021 | 468 | 116 | 58 | 127 | N/A |
12/31/2020 | 467 | 128 | 60 | 126 | N/A |
9/30/2020 | 465 | 133 | 83 | 122 | N/A |
6/30/2020 | 447 | 124 | 85 | 189 | N/A |
3/31/2020 | 443 | 127 | 30 | 171 | N/A |
12/31/2019 | 438 | 121 | 2 | 204 | N/A |
9/30/2019 | 410 | 112 | -109 | 140 | N/A |
6/30/2019 | 380 | 103 | -76 | 120 | N/A |
3/31/2019 | 330 | 81 | -60 | 99 | N/A |
12/31/2018 | 330 | 87 | 16 | 112 | N/A |
9/30/2018 | 314 | 73 | -8 | 111 | N/A |
6/30/2018 | 296 | 58 | N/A | 101 | N/A |
3/31/2018 | 314 | 55 | N/A | 109 | N/A |
12/31/2017 | 258 | 17 | N/A | 16 | N/A |
9/30/2017 | 244 | 21 | N/A | 26 | N/A |
6/30/2017 | 251 | -28 | N/A | -19 | N/A |
3/31/2017 | 231 | -28 | N/A | -50 | N/A |
12/31/2016 | 228 | -26 | N/A | 38 | N/A |
9/30/2016 | 218 | -37 | N/A | 37 | N/A |
6/30/2016 | 238 | 36 | N/A | 95 | N/A |
3/31/2016 | 250 | 41 | N/A | 107 | N/A |
12/31/2015 | 265 | 55 | N/A | 50 | N/A |
9/30/2015 | 237 | 22 | N/A | 33 | N/A |
6/30/2015 | 197 | -5 | N/A | 11 | N/A |
3/31/2015 | 181 | -9 | N/A | 17 | N/A |
12/31/2014 | 158 | -22 | N/A | 2 | N/A |
9/30/2014 | 175 | 6 | N/A | 19 | N/A |
6/30/2014 | 188 | 26 | N/A | 2 | N/A |
3/31/2014 | 194 | 34 | N/A | 15 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1786's forecast earnings growth is above the savings rate (1.1%).
Earnings vs Market: Insufficient data to determine if 1786's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if 1786's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1786's revenue (41.4% per year) is forecast to grow faster than the TW market (12.2% per year).
High Growth Revenue: 1786's revenue (41.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1786's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/03 09:43 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SciVision Biotech Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Weiyu Li | Capital Securities Corporation |